Literature DB >> 1534098

Regulation of MHC class I synthesis and expression by human neutrophils.

E Neuman1, J W Huleatt, H Vargas, E E Rupp, R M Jack.   

Abstract

Human peripheral blood neutrophils (PMN) treated with granulocyte-macrophage CSF (GM-CSF) increase the amount of class I 42-kDa H chain and 12-kDa L chain, beta 2-microglobulin (beta 2m), that they synthesize by 2.1- and 2.6-fold, respectively. To determine whether the increase in translation was associated with an increase in levels of class I H chain transcript, RNA blot analysis was performed on PMN that had been cultured in the presence of GM-CSF. Under no conditions were there increased levels of class I H chain transcript when class I heterodimer protein synthesis was increased. In addition, there was neither an increase in the synthesis of H chain mRNA, as measured by transcription assay, nor an alteration in the degradation rates of class I H chain transcript in PMN cultured with GM-CSF. In situ hybridization demonstrated that both the percentage of PMN that expressed class I transcript and the relative amounts of transcript per cell in GM-CSF-cultured PMN were the same as those in control PMN. Although there is increased translation of class I heterodimer in PMN treated with GM-CSF, there is no increase in its expression on the plasma membrane. The maintenance of constant levels of class I on the plasma membrane is dependent on continued protein synthesis and is maintained by release of class I heterodimer and free beta 2m into the medium. Heterodimer is released in the context of plasma membrane-derived vesicles, whereas beta 2m is released as a soluble protein. Maintenance of constant levels of class I heterodimer on the plasma membrane is also regulated by constitutive internalization. Up to 30% of class I molecules bearing 125I-Fab-labeled mAb to class I are internalized over 2 h at 37 degrees C. Therefore, inducible synthesis of class I by PMN is likely a consequence of post-transcriptional regulation, whereas the continued synthesis of class I heterodimer is required for maintenance of its expression. Furthermore, there is no increase in class I expression, in spite of increased synthesis, due to the release of class I heterodimer and beta 2m and the internalization of class I heterodimer from the plasma membrane. Thus, PMN are capable of post-transcriptional regulation of protein synthesis and are able to modulate the expression of plasma membrane proteins by regulated expression, release, and internalization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534098

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Cord blood CD8+ T-cell expansion following granulocyte transfusions eradicates refractory leukemia.

Authors:  Prashant Hiwarkar; Stuart Adams; Kimberly Gilmour; Ramya Nataraj; Denise Bonney; Kay Poulton; Robert Wynn
Journal:  Blood Adv       Date:  2020-09-08

2.  Physical association between the high-affinity IgG receptor (Fc gamma RI) and the gamma subunit of the high-affinity IgE receptor (Fc epsilon RI gamma).

Authors:  P R Scholl; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

3.  Disease and freeways drive genetic change in urban bobcat populations.

Authors:  Laurel E K Serieys; Amanda Lea; John P Pollinger; Seth P D Riley; Robert K Wayne
Journal:  Evol Appl       Date:  2014-12-02       Impact factor: 5.183

4.  IFN-γ alters the expression of diverse immunity related genes in a cell culture model designed to represent maturing neutrophils.

Authors:  Michael A Ellison; Christy M Gearheart; Christopher C Porter; Daniel R Ambruso
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

5.  In vivo interferon-gamma induced changes in gene expression dramatically alter neutrophil phenotype.

Authors:  Daniel R Ambruso; Natalie J Briones; Angelina F Baroffio; John R Murphy; Alexander D Tran; Katherine Gowan; Bridget Sanford; Michael Ellison; Kenneth L Jones
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.